About GNA Biosolutions
GNA Biosolutions is a company based in Planegg (Germany) founded in 2010 by Federico Francisco Bürsgens and Joachim Anton Stehr. GNA Biosolutions has raised $20.2 million across 3 funding rounds from investors including European Union, KfW and Mey Capital Matrix. The company has 29 employees as of December 31, 2020. GNA Biosolutions operates in a competitive market with competitors including Nanopore, PacBio, Omniome, Complete Genomics and OpGen, among others.
- Headquarter Planegg, Germany
- Employees 29 as on 31 Dec, 2020
- Founders Federico Francisco Bürsgens, Joachim Anton Stehr
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20.2 M (USD)
in 3 rounds
-
Latest Funding Round
$13.5 M (USD), Series C
Aug 05, 2019
-
Investors
European Union
& 9 more
-
Employee Count
29
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of GNA Biosolutions
Unlock access to complete
Unlock access to complete
Funding Insights of GNA Biosolutions
GNA Biosolutions has successfully raised a total of $20.2M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $13.5 million completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GNA Biosolutions
GNA Biosolutions has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, KfW and Mey Capital Matrix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Healthcare-focused private equity investments are managed by SHS Capital.
|
Locked | Locked | Locked | |
|
Investments are directed toward enterprise software, mobility, and industrial technologies.
|
Locked | Locked | Locked |
Investor details for GNA Biosolutions
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GNA Biosolutions
Investment portfolio details for GNA Biosolutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GNA Biosolutions
Detailed financials for GNA Biosolutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gna Biosolutions Comparisons
Peer comparison for GNA Biosolutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GNA Biosolutions
GNA Biosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Omniome, Complete Genomics and OpGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing technologies for applied genomic testing and medical sequencing
|
Detailed competitors of GNA Biosolutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gna Biosolutions
Complete news archive for GNA Biosolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GNA Biosolutions
GNA Biosolutions was founded in 2010 and raised its 1st funding round 5 years after it was founded.
GNA Biosolutions is headquartered in Planegg, Germany. It is registered at Planegg, Bavaria, Germany.
Federico Francisco Bürsgens is the current CEO of GNA Biosolutions. They have also founded this company.
GNA Biosolutions is a funded company, having raised a total of $20.2M across 3 funding rounds to date.
As of Dec 31, 2020, the latest employee count at GNA Biosolutions is 29.
Founded in 2010 and based in Planegg, Germany, instruments, OEM modules, and assays for molecular pathogen detection are developed by the company. A novel PCR approach with enhanced cooling and heating rates is utilized to support bacterial disease diagnosis in clinical settings. The initial product, Pharos400, incorporates laser-based PCR for thermal cycling and real-time result readout without fluorescence. Operations focus on the biotechnology sector serving physicians and hospitals.
GNA Biosolutions has 10 investors. Key investors include European Union, KfW, Mey Capital Matrix, SHS Capital, and UVC Partners.